19:17:58 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-11-21 15-10 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2024-05-23 Årsstämma 2024
2024-02-29 Extra Bolagsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-11-14 Extra Bolagsstämma 2023
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-29 Kvartalsrapport 2023-Q1
2023-05-26 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2023-02-10 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Kvartalsrapport 2020-Q1
2020-05-28 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017


ListaFirst North Stockholm
2cureX är verksamt inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Störst verksamhet innehas på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2023-11-23 08:30:00

2cureX AB (“2cureX”) hereby publishes the interim report for the third quarter of 2023. The interim report is available as an attached document as well as on the company’s website (https://www.2curex.com). A short summary of the report follows below.

CEO Fernando Andreu comments:

In October we shared a major update on our strategy. The core shift involves concentrating all our efforts on bringing IndiTreat® testing to hospitals worldwide swiftly and fast-track the development of an automated In Vitro Diagnostic (IVD) system. This decision has been brewing for a while, and despite Q3 showing improved results with discussions initiated in 46 new hospitals, 26 patient samples received, and revenue of 885K SEK (10% from commercial sales), it also highlighted a significant challenge.

To position ourselves as global leaders in the emerging Functional Drug Sensitivity Testing market (expected to reach multi-billion USD per year), we need to shift our business model. The focus now is on enabling in-house testing at customer labs, providing instruments, reagents, consumables, and software globally.

This is not a new strategy as we have envisioned the transition of IndiTreat® from service to product since our foundation. We have partnered, developed prototypes, and internally created a proprietary consumable concept ("drug cartridge"). Our plan involves accelerating the system's "industrialization" to achieve usability, serviceability, reliability, and manufacturing scalability. We will engage a Contract Development and Manufacturing Organization (CDMO) for this and meanwhile, we will continue offering IndiTreat® as a service, pushing the IGNITE program and clinical studies to expand our user base. The development project, ZENITH, is detailed in the report.

We believe refocusing on the automated system is the right move to unlock the full potential of Functional Drug Sensitivity Testing, making 2cureX a global leader. The efforts in product development, market reach, and regulatory compliance converge in this crucial project. It is a pathway to a more scalable and profitable business, creating opportunities for partnerships and value creation, aligning with shareholder expectations and we are thankful for the continued support in this new phase.

With a cash reserve of 18.1 MSEK, ongoing activities are secure into Q2 2024. To further fuel growth, 2cureX is exploring diverse options, including funding instruments, partnerships, and M&A, while acknowledging shareholders' unwavering support.”

Third quarter of 2023 (2023-07-01 until 2023-09-30) – the group

Net turnover for the period was 87 KSEK (0 KSEK).
Other operating income was 798 KSEK (395 KSEK)
The result before tax was -10 164 KSEK (-8 353 KSEK)
The result per share* was -0.58 SEK (-0.47 SEK)
The solidity** was 83 % (93 %).
The cash and bank were 18 104 KSEK (47 820 KSEK).

*Earnings per share: Profit for the period divided by the average number of shares. Average number of shares in third quarter of 2023: 17 602 916 shares. Total number of shares in 2cureX AB on September 30st, 2023: 17 602 916 shares.
**Equity ratio: Shareholder’s equity divided by total capital.

Significant events during the third quarter 2023


2cureX releases invitation for the Q2 2023 update and Q&A


2cureX publishes the interim report for Q2 2023

2cureX launches its first two IndiTreat products CE-marked under the new IVD Regulation


2cureX releases invitation for the Q3 2023 online presentation with a Q&A session

2cureX advances towards IVD-R compliance by securing a contract with a Notified Body

2cureX calls for an extraordinary General Meeting

2cureX releases a strategy update: Leapfrogging to the decentralization of IndiTreat testing through full focus on automation

2cureX participatd in the “Knæk Cancer” panel discussion


2cureX and its IndiTreat Image Uploader gets IVD CE-Mark

2cureX releases the bulleting from the Extraordinary General Meeting